Completed PHASE3 INTERVENTIONAL 2-arm NCT03417245

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

Sponsor: Genzyme, a Sanofi Company

Conditions Hemophilia A Hemophilia B

Interventions factor concentrates fitusiran

Updated 24 times since 2018 Last updated: Mar 15, 2022 Started: Mar 1, 2018 Primary completion: Jan 26, 2021 Completion: Jul 14, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03417245, this PHASE3 trial focuses on Hemophilia A and Hemophilia B and remains completed. Sponsored by Genzyme, a Sanofi Company, it has been updated 24 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

24 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Mar 2022 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 19 earlier versions

Sep 2021 — Mar 2022 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Apr 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3
Feb 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE3
Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Jul 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jun 2020 — Jul 2020 [monthly]

Recruiting PHASE3
May 2020 — Jun 2020 [monthly]

Recruiting PHASE3
Apr 2020 — May 2020 [monthly]

Recruiting PHASE3
Mar 2020 — Apr 2020 [monthly]

Recruiting PHASE3
Feb 2020 — Mar 2020 [monthly]

Recruiting PHASE3
Oct 2019 — Feb 2020 [monthly]

Recruiting PHASE3
Jun 2019 — Oct 2019 [monthly]

Recruiting PHASE3
Feb 2019 — Jun 2019 [monthly]

Recruiting PHASE3
Sep 2018 — Feb 2019 [monthly]

Recruiting PHASE3
Jul 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Feb 2018 — May 2018 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Akron, United States , Ampang, Malaysia , Ann Arbor, United States , Antalya, Turkey (Türkiye) , Bangalore, India , Beijing, China , Berlin, Germany , Budapest, Hungary , Busan, South Korea and 48 more locations